Moderna and Drug Discovery With AI

“So, there are plenty of failure points, and when you have hundreds of thousands or millions of something, something will eventually fail,” Peter Salanki, co-founder and CTO of CoreWeave, tells Bloomberg Intelligence Senior Technology Analyst Anurag Rana. “Instead of throwing out ...  Show more

The governance landscape for AI agents is evolving amid new developments around agentic workflows, says SailPoint President Matt Mills. He joins Bloomberg Intelligence analyst Mandeep Singh on this episode of the Tech Disruptors podcast. The conversation also explores how agentic ...  Show more

Greg Meyers, chief digital and technology officer at Bristol Myers Squibb, explains how AI is transforming pharmaceutical research from hypothesis-driven hunches to data-driven discoveries. Learn how the company is using computational chemistry to engineer breakthrough therapies ...  Show more

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ...  Show more

Shai Shen-Orr, co-founder and chief scientist at CytoReason and professor at the Technion, talks about the next frontier in healthcare: disease modeling. Shai shares how CytoReason bridges the gap between exploding biological data and actionable insight, powering smarter, faster ...  Show more

Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI i ...